{"id":5380,"date":"2022-06-28T23:30:37","date_gmt":"2022-06-28T23:30:37","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=5380"},"modified":"2023-08-29T17:54:37","modified_gmt":"2023-08-29T17:54:37","slug":"invex-therapeutics-uk-regulatory-approval-clinical-trial-presendin-treat-idiopathic-intracranial-hypertension","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=5380","title":{"rendered":"Invex Therapeutics \u83b7\u5f97\u82f1\u56fd\u76d1\u7ba1\u673a\u6784\u6279\u51c6 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u4e34\u5e8a\u8bd5\u9a8c"},"content":{"rendered":"<p>\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\uff0c\u53ef\u5728\u82f1\u56fd\u5f00\u59cb\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/p>\n<p>\u836f\u54c1\u548c\u4fdd\u5065\u54c1\u76d1\u7ba1\u673a\u6784 (Medicines and Healthcare Products Regulatory Agency; MHRA) \u6279\u51c6\u4e86\u8be5\u516c\u53f8\u5bf9\u5148\u5bfc\u836f\u7269 Presendin \u7684\u4e34\u5e8a\u8bd5\u9a8c\u6388\u6743\u3002<\/p>\n<p>\u968f\u540e\uff0c\u7814\u7a76\u4f26\u7406\u59d4\u5458\u4f1a\u63d0\u51fa\u4e86\u6709\u5229\u7684\u4f26\u7406\u610f\u89c1\uff0c\u8fd9\u662f\u5f00\u59cb\u8bd5\u9a8c\u4e4b\u524d\u7684\u4e00\u9879\u8981\u6c42\u3002<\/p>\n<p>EVOLVE \u662f\u4e00\u9879\u5b89\u6170\u5242\u5bf9\u7167\u3001\u53cc\u76f2\u8bd5\u9a8c\uff0c\u5c06\u5bf9 240 \u540d\u65b0\u8bca\u65ad\u7684 IIH \u60a3\u8005\u8fdb\u884c\u968f\u673a\u5206\u7ec4\uff0c\u4ee5\u786e\u5b9a Presendin \u4e0e\u5b89\u6170\u5242\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\uff0c\u6bcf\u5468\u7ed9\u836f\u4e00\u6b21\uff0c\u4e3a\u671f 24 \u5468\u3002<\/p>\n<p>\u4e3b\u8981\u7ec8\u70b9\u662f\u9885\u5185\u538b\u76f8\u5bf9\u4e8e\u57fa\u7ebf\u7684\u53d8\u5316\uff0c\u5173\u952e\u7684\u6b21\u8981\u7ec8\u70b9\u4e0e\u89c6\u529b\u548c\u5934\u75db\u7ed3\u679c\u6d4b\u91cf\u6709\u5173\u3002<\/p>\n<p>Invex \u6253\u7b97\u5728\u5168\u7403\u5f00\u8bbe\u591a\u8fbe 40 \u4e2a\u4e34\u5e8a\u7ad9\u70b9\u3002<\/p>\n<h2>\u91cd\u8981\u4e00\u6b65<\/h2>\n<p>Invex \u6267\u884c\u8463\u4e8b\u517c\u9996\u5e2d\u79d1\u5b66\u5b98 Alex Sinclair \u6559\u6388\u8868\u793a\uff0c\u76d1\u7ba1\u90e8\u95e8\u7684\u6279\u51c6\u662f\u8be5\u516c\u53f8\u5168\u7403\u7b2c\u4e09\u9636\u6bb5\u8bd5\u9a8c\u8ba1\u5212\u7684\u91cd\u8981\u4e00\u6b65\u3002<\/p>\n<p>\u201c\u82f1\u56fd\u65b0\u8bca\u65ad\u7684 IIH \u60a3\u8005\u5c06\u6709\u53ef\u80fd\u53c2\u4e0e\u8fd9\u9879\u8bd5\u9a8c\uff0c\u201d\u5979\u8bf4\u3002<\/p>\n<p>\u201c\u5728\u6211\u7684Birmingham\u8bca\u6240\uff0c\u6211\u7ecf\u5e38\u89c2\u5bdf IIH \u5bf9\u60a3\u8005\u53ca\u5176\u62a4\u7406\u4eba\u5458\u7684\u7834\u574f\u6027\u5f71\u54cd\uff0c\u4ee5\u53ca\u5728\u7f3a\u4e4f\u6807\u51c6\u836f\u7269\u7597\u6cd5\u7684\u60c5\u51b5\u4e0b\u7ba1\u7406\u8fd9\u79cd\u75be\u75c5\u7684\u76f8\u5173\u533b\u7597\u6210\u672c\u3002\u201d<\/p>\n<p>Invex \u7684\u7814\u7a76\u5c0f\u7ec4\u5df2\u5c06 IIH \u5bf9\u82f1\u683c\u5170\u7684\u7ecf\u6d4e\u6210\u672c\u5efa\u6a21\u4e3a\u5230 2030 \u5e74\u5c06\u63a5\u8fd1 5 \u4ebf\u82f1\u9551\uff088.8 \u4ebf\u6fb3\u5143\uff09\u3002<\/p>\n<p>\u4f8b\u5982\uff0c\u5728\u82cf\u683c\u5170\uff0c\u5728 15 \u81f3 44 \u5c81\u7684\u80a5\u80d6\u5973\u6027\u4e2d\uff0cIIH \u7684\u53d1\u75c5\u7387\u5df2\u5927\u5e45\u4e0a\u5347\u81f3\u6bcf 100,000 \u4eba\u4e2d\u7ea6 40 \u4f8b\uff0c\u8fd9\u88ab\u8ba4\u4e3a\u662f\u8be5\u56fd\u80a5\u80d6\u6c34\u5e73\u4e0d\u65ad\u4e0a\u5347\u7684\u76f4\u63a5\u540e\u679c\u3002<\/p>\n<h2>\u4e34\u5e8a\u7597\u6548<\/h2>\n<p>\u201cEVOLVE \u662f\u4e00\u9879\u91cd\u8981\u4e14\u53ca\u65f6\u7684\u8bd5\u9a8c\uff0c\u65e8\u5728\u4e86\u89e3\u6211\u4eec\u6bcf\u5468\u4e00\u6b21\u4f7f\u7528 Presendin \u6cbb\u7597\u8fd9\u4e9b\u60a3\u8005\u7684\u4e34\u5e8a\u7597\u6548\u548c\u5b89\u5168\u6027\uff0c\u201d\u8f9b\u514b\u83b1\u6559\u6388\u8bf4\u3002<\/p>\n<p>\u201c\u6211\u4eec\u5c06\u5728\u82f1\u56fd\u5f00\u8bbe\u591a\u4e2a\u4e34\u5e8a\u7ad9\u70b9\uff0c\u5e76\u5c06\u8fc5\u901f\u63a8\u8fdb\u673a\u6784\u5408\u540c\uff0c\u4ee5\u4fc3\u8fdb\u60a3\u8005\u62db\u52df\u7684\u5f00\u59cb\uff0c\u4ee5\u4fbf\u5728 6 \u6708 30 \u65e5\u4e4b\u540e\u5bf9\u7b2c\u4e00\u4e2a IIH \u60a3\u8005\u8fdb\u884c\u968f\u673a\u5316\u548c\u7ed9\u836f\u3002\u201d<\/p>\n<p>Invex \u7ee7\u7eed\u63a8\u8fdb\u5176 EVOLVE \u8bd5\u9a8c\u7684\u51c6\u5907\u6d3b\u52a8\uff0c\u5305\u62ec\u4e3a\u542f\u52a8\u7814\u7a76\u63d0\u4ea4\u989d\u5916\u7684\u76d1\u7ba1\u6587\u4ef6\uff0c\u5e76\u575a\u4fe1\u6fb3\u5927\u5229\u4e9a\u7684\u6240\u6709\u6279\u51c6\u5c06\u5728 9 \u6708\u5b63\u5ea6\u5b8c\u6210\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\uff0c\u53ef\u5728\u82f1\u56fd\u5f00\u59cb\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002 \u836f\u54c1\u548c\u4fdd\u5065\u54c1\u76d1\u7ba1\u673a\u6784 (Medicines and Healthcare Products Regulatory Agency; MHRA) \u6279\u51c6\u4e86\u8be5\u516c\u53f8\u5bf9\u5148\u5bfc\u836f\u7269 Presendin \u7684\u4e34\u5e8a\u8bd5\u9a8c\u6388\u6743\u3002 \u968f\u540e\uff0c\u7814\u7a76\u4f26\u7406\u59d4\u5458\u4f1a\u63d0\u51fa\u4e86\u6709\u5229\u7684\u4f26\u7406\u610f\u89c1\uff0c\u8fd9\u662f\u5f00\u59cb\u8bd5\u9a8c\u4e4b\u524d\u7684\u4e00\u9879\u8981\u6c42\u3002 EVOLVE \u662f\u4e00\u9879\u5b89\u6170\u5242\u5bf9\u7167\u3001\u53cc\u76f2\u8bd5\u9a8c\uff0c\u5c06\u5bf9 240 \u540d\u65b0\u8bca\u65ad\u7684 IIH \u60a3\u8005\u8fdb\u884c\u968f\u673a\u5206\u7ec4\uff0c\u4ee5\u786e\u5b9a Presendin \u4e0e\u5b89\u6170\u5242\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\uff0c\u6bcf\u5468\u7ed9\u836f\u4e00\u6b21\uff0c\u4e3a\u671f 24 \u5468\u3002 \u4e3b\u8981\u7ec8\u70b9\u662f\u9885\u5185\u538b\u76f8\u5bf9\u4e8e\u57fa\u7ebf\u7684\u53d8\u5316\uff0c\u5173\u952e\u7684\u6b21\u8981\u7ec8\u70b9\u4e0e\u89c6\u529b\u548c\u5934\u75db\u7ed3\u679c\u6d4b\u91cf\u6709\u5173\u3002 Invex \u6253\u7b97\u5728\u5168\u7403\u5f00\u8bbe\u591a\u8fbe 40 \u4e2a\u4e34\u5e8a\u7ad9\u70b9\u3002 \u91cd\u8981\u4e00\u6b65 Invex \u6267\u884c\u8463\u4e8b\u517c\u9996\u5e2d\u79d1\u5b66\u5b98 Alex Sinclair \u6559\u6388\u8868\u793a\uff0c\u76d1\u7ba1\u90e8\u95e8\u7684\u6279\u51c6\u662f\u8be5\u516c\u53f8\u5168\u7403\u7b2c\u4e09\u9636\u6bb5\u8bd5\u9a8c\u8ba1\u5212\u7684\u91cd\u8981\u4e00\u6b65\u3002 \u201c\u82f1\u56fd\u65b0\u8bca\u65ad\u7684 IIH \u60a3\u8005\u5c06\u6709\u53ef\u80fd\u53c2\u4e0e\u8fd9\u9879\u8bd5\u9a8c\uff0c\u201d\u5979\u8bf4\u3002 \u201c\u5728\u6211\u7684Birmingham\u8bca\u6240\uff0c\u6211\u7ecf\u5e38\u89c2\u5bdf IIH \u5bf9\u60a3\u8005\u53ca\u5176\u62a4\u7406\u4eba\u5458\u7684\u7834\u574f\u6027\u5f71\u54cd\uff0c\u4ee5\u53ca\u5728\u7f3a\u4e4f\u6807\u51c6\u836f\u7269\u7597\u6cd5\u7684\u60c5\u51b5\u4e0b\u7ba1\u7406\u8fd9\u79cd\u75be\u75c5\u7684\u76f8\u5173\u533b\u7597\u6210\u672c\u3002\u201d Invex \u7684\u7814\u7a76\u5c0f\u7ec4\u5df2\u5c06 IIH \u5bf9\u82f1\u683c\u5170\u7684\u7ecf\u6d4e\u6210\u672c\u5efa\u6a21\u4e3a\u5230 2030 \u5e74\u5c06\u63a5\u8fd1&hellip; <a class=\"more-link\" href=\"https:\/\/smallcapscn.x5view.co\/?p=5380\">Continue reading <span class=\"screen-reader-text\">Invex Therapeutics \u83b7\u5f97\u82f1\u56fd\u76d1\u7ba1\u673a\u6784\u6279\u51c6 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u4e34\u5e8a\u8bd5\u9a8c<\/span><\/a><\/p>\n","protected":false},"author":4,"featured_media":18776,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[273],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Invex Therapeutics \u83b7\u5f97\u82f1\u56fd\u76d1\u7ba1\u673a\u6784\u6279\u51c6 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u4e34\u5e8a\u8bd5\u9a8c<\/title>\n<meta name=\"description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\uff0c\u53ef\u5728\u82f1\u56fd\u5f00\u59cb\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invex Therapeutics \u83b7\u5f97\u82f1\u56fd\u76d1\u7ba1\u673a\u6784\u6279\u51c6 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u4e34\u5e8a\u8bd5\u9a8c\" \/>\n<meta property=\"og:description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\uff0c\u53ef\u5728\u82f1\u56fd\u5f00\u59cb\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-uk-regulatory-approval-clinical-trial-presendin-treat-idiopathic-intracranial-hypertension\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-28T23:30:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:54:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/INVEX-4.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Imelda Cotton\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Imelda Cotton\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-uk-regulatory-approval-clinical-trial-presendin-treat-idiopathic-intracranial-hypertension\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-uk-regulatory-approval-clinical-trial-presendin-treat-idiopathic-intracranial-hypertension\/\",\"name\":\"Invex Therapeutics \u83b7\u5f97\u82f1\u56fd\u76d1\u7ba1\u673a\u6784\u6279\u51c6 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u4e34\u5e8a\u8bd5\u9a8c\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2022-06-28T23:30:37+00:00\",\"dateModified\":\"2023-08-29T17:54:37+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\"},\"description\":\"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\uff0c\u53ef\u5728\u82f1\u56fd\u5f00\u59cb\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-uk-regulatory-approval-clinical-trial-presendin-treat-idiopathic-intracranial-hypertension\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-uk-regulatory-approval-clinical-trial-presendin-treat-idiopathic-intracranial-hypertension\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-uk-regulatory-approval-clinical-trial-presendin-treat-idiopathic-intracranial-hypertension\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invex Therapeutics \u83b7\u5f97\u82f1\u56fd\u76d1\u7ba1\u673a\u6784\u6279\u51c6 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u4e34\u5e8a\u8bd5\u9a8c\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\",\"name\":\"Imelda Cotton\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"caption\":\"Imelda Cotton\"},\"description\":\"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=4\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Invex Therapeutics \u83b7\u5f97\u82f1\u56fd\u76d1\u7ba1\u673a\u6784\u6279\u51c6 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u4e34\u5e8a\u8bd5\u9a8c","description":"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\uff0c\u53ef\u5728\u82f1\u56fd\u5f00\u59cb\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Invex Therapeutics \u83b7\u5f97\u82f1\u56fd\u76d1\u7ba1\u673a\u6784\u6279\u51c6 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u4e34\u5e8a\u8bd5\u9a8c","og_description":"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\uff0c\u53ef\u5728\u82f1\u56fd\u5f00\u59cb\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-uk-regulatory-approval-clinical-trial-presendin-treat-idiopathic-intracranial-hypertension\/","og_site_name":"smallcapsCN","article_published_time":"2022-06-28T23:30:37+00:00","article_modified_time":"2023-08-29T17:54:37+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/INVEX-4.jpg","type":"image\/jpeg"}],"author":"Imelda Cotton","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Imelda Cotton"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-uk-regulatory-approval-clinical-trial-presendin-treat-idiopathic-intracranial-hypertension\/","url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-uk-regulatory-approval-clinical-trial-presendin-treat-idiopathic-intracranial-hypertension\/","name":"Invex Therapeutics \u83b7\u5f97\u82f1\u56fd\u76d1\u7ba1\u673a\u6784\u6279\u51c6 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u4e34\u5e8a\u8bd5\u9a8c","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2022-06-28T23:30:37+00:00","dateModified":"2023-08-29T17:54:37+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e"},"description":"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\uff0c\u53ef\u5728\u82f1\u56fd\u5f00\u59cb\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-uk-regulatory-approval-clinical-trial-presendin-treat-idiopathic-intracranial-hypertension\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/invex-therapeutics-uk-regulatory-approval-clinical-trial-presendin-treat-idiopathic-intracranial-hypertension\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-uk-regulatory-approval-clinical-trial-presendin-treat-idiopathic-intracranial-hypertension\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Invex Therapeutics \u83b7\u5f97\u82f1\u56fd\u76d1\u7ba1\u673a\u6784\u6279\u51c6 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u4e34\u5e8a\u8bd5\u9a8c"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e","name":"Imelda Cotton","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","caption":"Imelda Cotton"},"description":"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.","url":"https:\/\/smallcapscn.x5view.co\/?author=4"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5380"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5380"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5380\/revisions"}],"predecessor-version":[{"id":15259,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5380\/revisions\/15259"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/18776"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}